Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885 | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885

Wong KA, Worth A, Martin R, Svarovskaia ES, Brainard DM, Lawitz EJ, et al. Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother. 2013;57(12):6333-6340.

Publication Type:

Journal Article

Authors:

Wong, K.A.; Worth, A.; Martin, R.; E. S. Svarovskaia; Brainard, D.M.; E J Lawitz; Miller, M.D.; Mo, H.

Source:

Antimicrob Agents Chemother, Volume 57, Issue 12, p.6333-6340 (2013)

Keywords:

Amino Acid Substitution, analysis, antagonists & inhibitors, Antiviral Agents, Benzimidazoles, chronic HCV, CLASS, clinical trial, drug effects, Drug Resistance,Viral, drug therapy, Fluorenes, genetics, Genotype, HCV, Hepacivirus, hepatitis, Hepatitis C, hepatitis C virus, Hepatitis C,Chronic, Humans, In Vitro, interferon, Interferon-alpha, monotherapy, Mutation, NS5A inhibitor, phenotypic, Proteins, Research, Research Support, resistance, Ribavirin, Rna, therapeutic use, treatment, Treatment Outcome, treatment-naive, Viral Load, Viral Nonstructural Proteins, virology

Notes:

PMC3837913

Cited On:

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/23877691

Export Citation:

RIS Format

Top